title: Intracameral triamcinolone acetonide in glaucoma surgery: a prospective randomized controlled trial.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of intracameral triamcinolone acetonide (TA) in glaucoma surgery.
  
  
  METHODS
  Prospective randomized clinical trial.
  
  
  METHODS
  
  
  
  METHODS
  Institutional-Wills Eye Hospital.
  
  
  METHODS
  Patients undergoing trabeculectomy (with or without cataract surgery) or tube shunt surgery.
  
  
  METHODS
  Patients were randomized to receive intracameral TA or balanced salt solution at the end of surgery. Follow-up time was 6 months.
  
  
  METHODS
  Intraocular pressure, visual acuity, inflammation measured by slit-lamp examination and laser flare meter, cataract grading, bleb appearance, dry eye scores, use of supplemental medical therapy, surgical success, and rate of complications.
  
  
  RESULTS
  Seventy-seven patients were enrolled in the study, including 37 in the TA group and 40 in the control group. There were no significant differences in success rates between the 2 groups (P=.60). Intraocular pressure and medication use were similar between the groups for each follow-up visit. Dry eye scores were lower in the TA group at month 1 (P=.042), while flare scores were higher in the TA group on day 1 (P=.015) but lower at month 1 (P=.044). The complication rates were higher in the TA group on day 1 (P=.04). All other outcome measures were similar for both groups.
  
  
  CONCLUSIONS
  Intracameral TA did not affect the success rates or change the complication rates of glaucoma surgery.
authors.affiliation: Glaucoma Research Center, Wills Eye Hospital, Philadelphia, Pennsylvania.
authors.forename: Michael S
authors.initials: MS
authors.lastname: Koval
authors.affiliation: Glaucoma Research Center, Wills Eye Hospital, Philadelphia, Pennsylvania. Electronic address: marlenemoster@aol.com.
authors.forename: Marlene R
authors.initials: MR
authors.lastname: Moster
authors.affiliation: Glaucoma Research Center, Wills Eye Hospital, Philadelphia, Pennsylvania.
authors.forename: Kathryn B
authors.initials: KB
authors.lastname: Freidl
authors.affiliation: Glaucoma Research Center, Wills Eye Hospital, Philadelphia, Pennsylvania.
authors.forename: Michael
authors.initials: M
authors.lastname: Waisbourd
authors.affiliation: Glaucoma Research Center, Wills Eye Hospital, Philadelphia, Pennsylvania.
authors.forename: Shelly G
authors.initials: SG
authors.lastname: Jain
authors.affiliation: Glaucoma Research Center, Wills Eye Hospital, Philadelphia, Pennsylvania.
authors.forename: Parul
authors.initials: P
authors.lastname: Ichhpujani
authors.affiliation: Glaucoma Research Center, Wills Eye Hospital, Philadelphia, Pennsylvania.
authors.forename: Jonathan S
authors.initials: JS
authors.lastname: Myers
authors.affiliation: Glaucoma Research Center, Wills Eye Hospital, Philadelphia, Pennsylvania.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Pro
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D005901:Glaucoma / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery*; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D056965:Injections, Intraocular; D007429:Intraocular Pressure; D007432:Intraoperative Period; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014130:Trabeculectomy / Q000379:methods*; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*
chemical_list: D005938:Glucocorticoids; D014222:Triamcinolone Acetonide